Pseftogas A - Search Results

1

Down-regulation of the Tumor Suppressor CYLD Enhances the Transformed Phenotype of Human Breast Cancer Cells.

Orfanidou T, Xanthopoulos K, Dafou D, Pseftogas A, Hadweh P, Psyllaki C, Hatzivassiliou E, Mosialos G. Orfanidou T, et al. Among authors: pseftogas a. Anticancer Res. 2017 Jul;37(7):3493-3503. doi: 10.21873/anticanres.11717. Anticancer Res. 2017. PMID: 28668838

2

Inactivation of CYLD in intestinal epithelial cells exacerbates colitis-associated colorectal carcinogenesis - a short report.

Karatzas DN, Xanthopoulos K, Kotantaki P, Pseftogas A, Teliousis K, Hatzivassiliou EG, Kontoyiannis DL, Poutahidis T, Mosialos G. Karatzas DN, et al. Among authors: pseftogas a. Cell Oncol (Dordr). 2016 Jun;39(3):287-93. doi: 10.1007/s13402-016-0279-3. Epub 2016 Apr 4. Cell Oncol (Dordr). 2016. PMID: 27042826

3

Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects.

Pseftogas A, Gonidas C, Mosialos G. Pseftogas A, et al. Int J Biochem Cell Biol. 2017 Jan;82:49-56. doi: 10.1016/j.biocel.2016.11.011. Epub 2016 Nov 16. Int J Biochem Cell Biol. 2017. PMID: 27865894

4

HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice.

Afaloniati H, Angelopoulou K, Giakoustidis A, Hardas A, Pseftogas A, Makedou K, Gargavanis A, Goulopoulos T, Iliadis S, Papadopoulos V, Papalois A, Mosialos G, Poutahidis T, Giakoustidis D. Afaloniati H, et al. Among authors: pseftogas a. Onco Targets Ther. 2020 Jun 15;13:5575-5588. doi: 10.2147/OTT.S250233. eCollection 2020. Onco Targets Ther. 2020. PMID: 32606772 Free PMC article.

5

The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGF Signaling.

Pseftogas A, Xanthopoulos K, Poutahidis T, Ainali C, Dafou D, Panteris E, Kern JG, Varelas X, Hardas A, Gonidas C, Tsingotjidou A, Hatzivassiliou E, Mosialos G. Pseftogas A, et al. Cancers (Basel). 2020 Jul 24;12(8):2047. doi: 10.3390/cancers12082047. Cancers (Basel). 2020. PMID: 32722292 Free PMC article.

6

Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency.

Bekas N, Samiotaki M, Papathanasiou M, Mokos P, Pseftogas A, Xanthopoulos K, Thanos D, Mosialos G, Dafou D. Bekas N, et al. Among authors: pseftogas a. Cancers (Basel). 2023 Oct 15;15(20):4997. doi: 10.3390/cancers15204997. Cancers (Basel). 2023. PMID: 37894364 Free PMC article.

7

IκBε deficiency accelerates disease development in chronic lymphocytic leukemia.

Bordini J, Lenzi C, Frenquelli M, Morabito A, Pseftogas A, Belloni D, Mansouri L, Tsiolas G, Perotta E, Ranghetti P, Gandini F, Genova F, Hägerstrand D, Gavriilidis G, Keisaris S, Pechlivanis N, Davi F, Kay NE, Langerak AW, Pospisilova S, Scarfò L, Makris A, Psomopoulos FE, Stamatopoulos K, Rosenquist R, Campanella A, Ghia P. Bordini J, et al. Among authors: pseftogas a. Leukemia. 2024 Jun;38(6):1287-1298. doi: 10.1038/s41375-024-02236-4. Epub 2024 Apr 4. Leukemia. 2024. PMID: 38575671

8

Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to Breast Cancer Development.

Pseftogas A, Xanthopoulos K, Siasiaridis A, Poutahidis T, Gonidas C, Tsingotjidou A, Hatzivassiliou E, Mosialos G. Pseftogas A, et al. Anticancer Res. 2024 May;44(5):1885-1894. doi: 10.21873/anticanres.16990. Anticancer Res. 2024. PMID: 38677721

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters